← All tickers

Is NTLA Worth Buying in 2026?

Intellia Therapeutics, Inc

STOCK IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES Updated 2026-06-14

Here’s whether Intellia Therapeutics, Inc (NTLA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: 50-day MA is rising (+0.40% over 10 days); RSI 47 — healthy momentum range; strong 1-year return of +45.0%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 3-month momentum negative (-9.5%). Currently 57.1% off its 52-week high. Score: -1/7.

Ready to act on this? 📈 Trade on Webull

NTLA is trading below its 200-day MA ($13.39) — a key warning sign the longer-term trend is under pressure. An RSI of 46.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +45.0% compares to +22.9% for SPY (beat the market by 22.2%). The current 57.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $14,503 today
vs. S&P 500 (SPY) — same period beat market by 22.2%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✗Above 200-day MA ($13.39)
✗Above 50-day MA ($13.63)
✓RSI(14) neutral zone (30–70) — currently 46.6
✓Positive return (+45.0%)
!Within 10% of period high (−57.1%)
Period Range $12.11
$7.95 $28.25
RSI (14) 46.6
0 · OversoldOverbought · 100

Key Metrics

Price$12.11
Period Return+45.0%
Period High$28.25
Period Low$7.95
Drawdown−57.1%
MA-50$13.63
MA-200$13.39
RSI (14)46.6
Avg Volume (30d)6.1M
vs. SPYbeat by 22.2%
Return Rank#362 of 1246

Trade NTLA

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers